What drug should I switch to after becoming resistant to adagrasib?

Adagrasib (Adagrasib) is a prescription drug used to treat adults with non-small cell lung cancer (NSCLC) whose tumors have an abnormal KRAS G12C gene. Adagrasib is designed to attack mutated KRAS proteins to inhibit tumor growth. When patients develop resistance to adagrasib, doctors often consider other treatment options. Here are some possible alternative medications or treatment strategies:

1. Patients can try other anti-cancer drugs that target KRAS G12C mutation, such as Sotorasib (Sotorasib), which has been approved for the treatment of non-small cell lung cancer. Drugs may have different chemical structures and mechanisms of action and therefore may have different effects on drug resistance.

2. Doctors may consider combination therapy, that is, combining adagrasiib with other drugs. For example, it can be used in combination with immunotherapy drugs, chemotherapy drugs or other targeted drugs to enhance the therapeutic effect.

3.If applicable, your doctor may recommend participation in a clinical trial to explore new treatment options. Clinical trials offer patients the opportunity to receive drugs or new treatment strategies that have not yet been approved.

Importantly, treatment decisions should be made by a professional physician on a case-by-case basis for each patient. They will consider the patient's condition, genetic variation, drug resistance and other factors to determine the best treatment plan.

Sinceadagrasibthe original drug has not yet been launched in China, patients can only purchase adagrasib through overseas channels, and the U.S. original version of 200mg*180 tablets is priced at hundreds of thousands of yuan per box (the price may fluctuate due to exchange rates), which is very expensive. Currently, there are no generic drugs of adagrasib produced overseas. For more drug information and specific prices, please consult Yaode’s medical consultant.